Allakos to be acquired by Concentra Biosciences for 33c per share in cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Merger Agreement: Allakos has agreed to be acquired by Concentra Biosciences for $0.33 per share, with the Board of Directors supporting the decision as beneficial for shareholders.
Tender Offer and Conditions: A tender offer will begin by April 15, 2025, requiring a majority of shares to be tendered and $35.5 million in cash available at closing, with the merger expected to finalize in May 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
